AlloSource Announces New Possibilities In Wound Care

Company launches AlloSkin™ AC and announces updated reimbursement coverage for AlloSkin™ RT

News provided by

Apr 29, 2015, 12:18 ET

CENTENNIAL, Colo., April 29, 2015 /PRNewswire-USNewswire/ -- AlloSource®, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, announced the launch of AlloSkin™ AC, an acellular dermal allograft. The Centers for Medicare & Medicaid Services (CMS) also moved AlloSkin™ RT, a meshed human dermal graft, from the low-cost to the high-cost category for reimbursement.

"AlloSource is committed to bringing cost-effective wound and burn care solutions to market that meet a genuine medical need," said Peter Stevens, PhD, MBA, AlloSource Vice President of Strategy, Development and Growth. "The launch of AlloSkin AC and the updated coverage for AlloSkin RT are both great accomplishments as we continue to provide innovative allografts while honoring the gift of human tissue donation."

AlloSkin AC is a decellularized, meshed, dermis-only skin allograft. The resulting acellular matrix is a favorable microenvironment for bio-ingrowth, acting as a scaffold onto which the body can build dermal tissue through revascularization and cellular repopulation. Acellular dermal tissue is used clinically in the treatment of partial and full-thickness burns, traumatic tissue loss due to injury and for chronic wounds such as pressure ulcers, diabetic foot ulcers and venous and arterial ulcers. AlloSkin AC has Outpatient Medicare reimbursement coverage under the Novitas Administrative Contract.

AlloSkin RT has broad clinical applications for acute and chronic wound therapy and is a ready-to-use, shelf-stable graft with room temperature storage. CMS' new high-cost category coverage for AlloSkin RT is a result of new regulations in 2014 for skin substitutes, which are divided into high- and low-cost categories for bundled product and application payment within Hospital Outpatient Departments.

AlloSource will be highlighting its wound care portfolio at the Symposium on Advanced Wound Care at booth 320 in San Antonio, Texas from April 29 – May 3, 2015.

About AlloSource
AlloSource is one of the largest nonprofit cellular and tissue networks in the country, offering more than 200 types of precise cartilage, cellular, bone, skin and soft-tissue allografts to advance patient healing. For more than 20 years, AlloSource's products have bridged the proven science of allografts with the advanced technology of cells, offering life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. As the world's largest processor of cellular bone allografts, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource delivers unparalleled expertise and service to its growing network of surgeons, partners, and the country's most reputable organ procurement organizations. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org or our educational website, allograftpossibilities.org.

Media Contact
Megan Duggan
AlloSource
720. 382. 2766
[email protected]

SOURCE AlloSource